Director, Financial Planning and Analysis, Clinical

The role

The Director, Financial Planning and Analysis, Clinical will manage planning processes and serve as a business partner to the Clinical and Medical Affairs organizations. This role assists the VP of FP&A on overall planning process strategy and management and interacts with the accounting team on month end closing.

What you will do

• FP&A business partner to the Clinical and Medical Affairs organizations, and BEAM-302 and BEAM-301 programs.
• Oversee planning cycle activities and review and ensure accuracy of plan data for all partner functions and programs.
• Conduct monthly budget vs. actual analysis for partner functions and programs, and finance/management results.
• Track risks and opportunities to the annual budget and enter material changes into rolling forecast.
• Assist in the overall budget, LRP, and forecast processes outside of partnership duties.
• Partner with Sourcing on contract and change order reviews for significant Clinical Trial Agreements.
• Attend monthly Clinical accrual meetings to ensure accuracy of expense and SOX compliance.
• Attend quarterly milestone meetings to ensure accuracy of expense and future projections in forecast.
• Special projects as required.

Required qualifications

• Typically 12+ years of experience with 8+ years of FP&A experience
• Bachelor’s degree in finance or accounting or equivalent
• Financial statement knowledge and understanding of US GAAP
• Strong team player that has a customer service approach and is solution oriented
• Ability to work within and meet all deadlines while executing on multiple deliverables
• Enjoy working in a fast-paced, high-volume environment
• Comfort utilizing and incorporating available AI tools into work processes
• Advanced understanding of Excel, Adaptive Insights, and ERP systems

Nice to have

• biotech industry experience strongly preferred
• NetSuite or SAP

About the company

Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. The company uses base editing technology to advance a diversified portfolio of base editing programs.